UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of oncology, 2019-08, Vol.30 (8), p.1321-1328

2019

Volltextzugriff (PDF)

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50

Cancer Immunology, Immunotherapy, 2023-06, Vol.72 (6), p.1881-1890

2023

Volltextzugriff (PDF)

Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors

Cancer Immunology, Immunotherapy, 2022-11, Vol.71 (11), p.2609-2618

2022

Volltextzugriff (PDF)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50

Cancer Immunology, Immunotherapy, 2023-06, Vol.72 (6), p.1891-1892

2023

Volltextzugriff (PDF)

A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study

Annals of oncology, 2019-04, Vol.30, p.ii66-ii66

2019

Volltextzugriff (PDF)

SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.1227-1227

2020

Volltextzugriff (PDF)

Explore-ALK : étude de cohorte prospectif non interventionnelle, nationale et multicentrique de patients atteints de cancer bronchopulmonaire non à petites cellules caractérisés par un réarrangement ALK. Caractéristiques cliniques et biologiques des 100 premiers patients de la cohorte

Revue des maladies respiratoires actualités, 2023, Vol.15 (1), p.137-138

2023

Volltextzugriff (PDF)

Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data

Annals of oncology, 2018-11, Vol.29, p.ix152-ix152

2018

Volltextzugriff (PDF)

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

Respiratory medicine and research, 2020-11, Vol.78, p.100788-100788, Article 100788

2020

Volltextzugriff (PDF)

Importance of Using Complementary Process Analyzers for the Process Monitoring, Analysis, and Understanding of Freeze Drying

Analytical chemistry (Washington), 2009-09, Vol.81 (18), p.7639-7649

2009

Volltextzugriff (PDF)

Management of non-small cell lung cancer patients harboring activating mutations and CNS progression

Revue des maladies respiratoires, 2019-05, Vol.36 (5), p.583

2019

Volltextzugriff (PDF)

Iris metastasis presenting as monocular diplopia

Journal francais d'ophtalmologie, 2016-12, Vol.39 (10), p.e275

2016

Volltextzugriff (PDF)

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838

2017

Volltextzugriff (PDF)

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

The New England journal of medicine, 2018-06, Vol.378 (24), p.2288-2301

2018

Volltextzugriff (PDF)

1461P Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)

Annals of oncology, 2023-10, Vol.34, p.S830-S830

2023

Volltextzugriff (PDF)

1314P Preliminary results of sequential combination of immunotherapy followed by chemotherapy in advanced non-small cell lung cancer

Annals of oncology, 2021-09, Vol.32, p.S1012-S1012

2021

Volltextzugriff (PDF)

1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial

Annals of oncology, 2023-10, Vol.34, p.S791-S792

2023

Volltextzugriff (PDF)

1292P A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)

Annals of oncology, 2024-09, Vol.35, p.S823-S823

2024

Volltextzugriff (PDF)

1311P Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial

Annals of oncology, 2024-09, Vol.35, p.S834-S834

2024

Volltextzugriff (PDF)

985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC

Annals of oncology, 2022-09, Vol.33, p.S1002-S1003

2022

Volltextzugriff (PDF)

1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy

Annals of oncology, 2022-09, Vol.33, p.S1052-S1053

2022

Volltextzugriff (PDF)

Freeze-drying process monitoring using a cold plasma ionization device

PDA journal of pharmaceutical science and technology, 2007-05, Vol.61 (3), p.160

2007

Volltextzugriff (PDF)

1113P Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50

Annals of oncology, 2022-09, Vol.33, p.S1060

2022

Volltextzugriff (PDF)

24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy

Annals of oncology, 2022-04, Vol.33, p.S40-S41

2022

Volltextzugriff (PDF)

Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION

International journal of radiation oncology, biology, physics, 2022-02, Vol.112 (2), p.e14-e15

2022

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(172)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(93)
Humans
(87)
Life Sciences & Biomedicine
(78)
Female
(46)
Male
(45)
Biological And Medical Sciences
(44)
Adult
(43)
Middle Aged
(35)
Medical Sciences
(25)
Nutrition & Dietetics
(22)
Aged
(20)
Fundamental And Applied Biological Sciences. Psychology
(19)
Life Sciences
(14)
Physical Sciences
(13)
Aged, 80 And Over
(12)
Chemistry
(12)
Lactation
(12)
Diet
(11)
Animals
(10)
Chemistry, Analytical
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50

Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50

A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study

SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS

Explore-ALK : étude de cohorte prospectif non interventionnelle, nationale et multicentrique de patients atteints de cancer bronchopulmonaire non à petites cellules caractérisés par un réarrangement ALK. Caractéristiques cliniques et biologiques des 100 premiers patients de la cohorte

Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

Importance of Using Complementary Process Analyzers for the Process Monitoring, Analysis, and Understanding of Freeze Drying

Management of non-small cell lung cancer patients harboring activating mutations and CNS progression

Iris metastasis presenting as monocular diplopia

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

1461P Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)

1314P Preliminary results of sequential combination of immunotherapy followed by chemotherapy in advanced non-small cell lung cancer

1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial

1292P A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)

1311P Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial

985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC

1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy

Freeze-drying process monitoring using a cold plasma ionization device

1113P Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50

24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy

Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION

Suchergebnisse filtern